Mission: Affordable—GSK, Bharat Biotech Slash Malaria Shot Costs

Image Source: Homeland Preparedness News

As a significant stimulus for global health equity, Bharat Biotech and GlaxoSmithKline (GSK) have announced that they intend to reduce the price of the world's first malaria vaccine, RTS,S/AS01E, by more than half by 2028. This is as part of a long-term approach to promote sustainable and affordable access to the vaccine in areas where malaria is endemic, especially in sub-Saharan Africa.

Why It Matters

Malaria remains a leading cause of death among children, with over 600,000 deaths annually, mostly in Africa.
GSK's RTS,S/AS01E malaria vaccine, co-manufactured with Bharat Biotech, is the first licensed malaria vaccine in the world.
Lower prices will enable broader roll-out through Gavi-supported immunization programs to reach millions of vulnerable children.

The Partnership

GSK has transferred production of the antigen component of the vaccine to Bharat Biotech while continuing to supply the adjuvant (vaccine booster).
Bharat Biotech is scaling up production to meet growing demand, with support from global health partners including PATH, WHO, and UNICEF.

Pricing Outlook

The current cost of the vaccine is expected to drop by more than 50% by 2028, making it significantly more accessible for low-income countries.
The price reduction aligns with Gavi’s long-term procurement strategy and WHO’s goal of universal malaria vaccine access.

Sources: GSK Press Release, Economic Times, UNICEF